|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009429,
umls-concept:C0010927,
umls-concept:C0013216,
umls-concept:C0025202,
umls-concept:C0205087,
umls-concept:C0205099,
umls-concept:C0442711,
umls-concept:C0556895,
umls-concept:C0677874,
umls-concept:C1274040,
umls-concept:C1518578
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1984-3-23
|
|
pubmed:abstractText |
The results of three Phase III studies of DTIC in 580 patients with metastatic melanoma were reviewed to evaluate the subsequent course of 26 patients who achieved a complete response (CR) to chemotherapy. The majority (17 of 26) of these patients had soft tissue metastases. Six of the 26 patients remained in CR at last report (30-259 weeks), two died of other causes while remaining free of melanoma, and 18 relapsed and died. Ninety-five percent of the 26 patients were alive at 1 year, and survival was 31.1% at 72 months. Seven of the eight patients with sustained remission received chemotherapy for at least 6 months after CR developed, whereas 10 of 18 relapsing patients were treated for less than 6 months after CR was achieved. Long-term sustained CR to chemotherapy occurs in 1% to 2% of patients treated with DTIC, and late relapse is rare in patients who remain in CR for 2 years.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1299-305
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:6362841-Adult,
pubmed-meshheading:6362841-Aged,
pubmed-meshheading:6362841-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:6362841-Carmustine,
pubmed-meshheading:6362841-Clinical Trials as Topic,
pubmed-meshheading:6362841-Dacarbazine,
pubmed-meshheading:6362841-Female,
pubmed-meshheading:6362841-Humans,
pubmed-meshheading:6362841-Hydroxyurea,
pubmed-meshheading:6362841-Lomustine,
pubmed-meshheading:6362841-Male,
pubmed-meshheading:6362841-Melanoma,
pubmed-meshheading:6362841-Middle Aged,
pubmed-meshheading:6362841-Neoplasm Recurrence, Local,
pubmed-meshheading:6362841-Retrospective Studies,
pubmed-meshheading:6362841-Sex Factors,
pubmed-meshheading:6362841-Skin Neoplasms,
pubmed-meshheading:6362841-Soft Tissue Neoplasms,
pubmed-meshheading:6362841-Time Factors,
pubmed-meshheading:6362841-Vincristine
|
|
pubmed:year |
1984
|
|
pubmed:articleTitle |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|
